Tencent and Legal & General led a $50m Series C funding round in Congenica, a digital health company. Additional investors include Xeraya, Puhua Capital, IDO Investments, Parkwalk, Cambridge Innovation Capital and Downing. "Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors to Congenica and are grateful to our existing investors for their continued support," David Atkins, Congenica CEO.